Leidos Holdings, Inc. - LDOS STOCK NEWS

Leidos Holdings, Inc. (NYSE:LDOS) has declared a quarterly cash dividend of $0.36 per share, payable on June 30, 2022, to stockholders of record as of June 15, 2022. The announcement reflects the company's commitment to returning value to its shareholders. Leidos, a leader in technology and engineering solutions, reported annual revenues of approximately $13.7 billion for the fiscal year ending December 31, 2021, with 43,000 employees supporting vital missions across various sectors.

Leidos (NYSE: LDOS) has commenced construction on a new facility at Campus Point in San Diego, California, expected to be completed by mid-2024. This state-of-the-art building will enhance corporate real estate efficiency for employees and customers, hosting over 400 staff with secure spaces for classified programs. The project, developed by Alexandria Real Estate Equities, focuses on advancing technologies at the Leidos Innovations Center. Additionally, Leidos announced a $25,000 contribution to the Salvation Army, supporting the local community.

Leidos (NYSE: LDOS) has announced a conference call on May 3, 2022, at 8 a.m. ET to discuss its financial results for the first quarter ending April 1, 2022. A press release detailing quarterly earnings will be issued prior to the call. Investors can access the call via the internet or telephone, with replay options available after the event. Leidos reported approximately $13.7 billion in annual revenues for 2021 and operates across defense, intelligence, civil, and health markets.

Leidos (NYSE:LDOS) announced the appointment of Steve Cook as Dynetics Group President, effective April 1. Paul Engola will serve as Deputy Group President. Cook, previously the deputy group president and operations manager, has extensive experience in space technologies and led various projects at NASA. The leadership transition aims to enhance the company’s presence in the national security space market. Dave King will remain as a consultant during the transition, ensuring continuity in strategic initiatives.

The Leidos Partnership for Defense Health (LPDH) announced the successful deployment of the MHS GENESIS electronic health record system to 15,000 clinicians across 14 Military Treatment Facility Commands in five states. This marks the largest double Wave deployment to date, expanding the system's operational capacity to 1,360 locations with over 92,000 active users. The project remains on schedule and within budget, with nine additional deployments planned through the end of 2023, aiming for full implementation by year-end.

Leidos (NYSE: LDOS) has secured a prime contract valued at $84 million from the U.S. Navy's NAVWAR to enhance undersea warfare systems. This task order spans one year with four additional option years. Operations will be conducted in Virginia and Japan. The contract involves providing operations and maintenance teams for the USNS Tactical Auxiliary General Ocean Surveillance vessels and engineering support for the Surveillance Towed Array Sensor System fleet.

Leidos (NYSE: LDOS) will participate in the J.P. Morgan 2022 Industrials Conference on March 17, 2022, at 1:20 p.m. ET in New York City. CEO Roger Krone will present, and a live audio webcast will be accessible on the Leidos Investor Relations website. A replay will be available for 30 days post-event. Leidos, a leading science and technology company headquartered in Reston, Virginia, reported $13.7 billion in revenues for the fiscal year ending December 31, 2021.

Leidos (NYSE:LDOS) secured a prime contract worth up to $545 million from the National Institute of Allergy and Infectious Diseases (NIAID) on March 9, 2022. This seven-year contract will enhance biomedical preclinical and development capabilities. Services include chemistry manufacturing, bioinformatics, and analytics. Leidos has supported U.S. biomedical research for over two decades, managing large contracts related to various diseases. The company reported $13.7 billion in revenue for fiscal 2021, underscoring its strong market presence.